Who owns Oculis Holding AG (OCS)? Elite investor 13F holders
2 tracked elite investors reported holding Oculis Holding AG as of 2026-06-30, including Tudor Investment, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Tudor Investment | OCULIS HOLDING AG | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 430261.00 USD | 31021.000000 | Shares | add | Original filing |
| D.E. Shaw | OCULIS HOLDING AG | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 173580.00 USD | 34716.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.